2[1]Le chevalier T, Brisgand D, DouilandJY, et al. randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients [J]. J Clin Oncol, 1994, 12(2): 360～367
3[3]Miller TP, Vance RB, Ahmann FR, et al. Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MIPE): A southwest oncology group Study[J]. Cancer Treat Rep,1986, 70(9): 1101～1110
4[4]Baldini E, Tibaldi C, Ardizzoni A, et al. Cisplatin-vindesine-mitomyvin (MVP) Vs cisplatin-ifosfamide-vinorelbine (PIN) Vs carboplatin vinoprelbine (CaN) in patients with advanced nonsmall cell lung cancer: a FONICAP randomized phase study[J]. Br J Cancer, 1998, 77(12): 2367～2370
5[5]Perol M, GuerinJC, Thomas P, et al. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatinmitomycin-vindesine in advanced non-small cell lung cancer [J].Lung Cancer, 1996, 14(1): 119～134
6[6]Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial [J]. J Clin Oncol , 2001, 19(13):3210～3218
7[7]Wozniak AJ, Growley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer:asouthwest oncology group study[J].J Clin Oncol, 1998, 16(7): 2459～ 2465
8[9]Giaccone G, Splinte TAW, Debruyne C, et al. Randomized study of paclitaxel cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer [J]. J Clin Oncol, 1998, 16(6):2133～2141
9[10]Breathnach OS, Georgiadis MS, Schuler BS, et al. Phase trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer[J].Clin Cancer Res, 2000, 6(7):2670～2676
